Plasma α-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study
| Autor: | Hua Wang, Tessandra Stewart, Jing Zhang, Patrick Aro, Pars Investigators, Min Shi, Carmen Ginghina, Danna Jennings, John Seibyl, Kenneth Marek, Poul Henning Jensen, Anzari Atik, Kathleen F. Kerr |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Risk 0301 basic medicine Oncology medicine.medical_specialty Parkinson's Pilot Projects Disease Article lcsh:RC321-571 Prodromal phase Plasma 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine mental disorders medicine Humans Cognitive Dysfunction Longitudinal Studies Cognitive decline Cognitive impairment lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry Aged Dopamine transporter α-Synuclein biology business.industry Parkinson Disease Cognition Middle Aged nervous system diseases Cross-Sectional Studies 030104 developmental biology nervous system Neurology Prodromal Potential biomarkers alpha-Synuclein biology.protein Female α synuclein business Biomarkers 030217 neurology & neurosurgery Follow-Up Studies |
| Zdroj: | Neurobiology of Disease, Vol 116, Iss, Pp 53-59 (2018) PARS Investigators 2018, ' Plasma α-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome : A pilot study ', Neurobiology of Disease, vol. 116, pp. 53-59 . https://doi.org/10.1016/j.nbd.2018.04.015 |
| ISSN: | 0969-9961 |
| DOI: | 10.1016/j.nbd.2018.04.015 |
| Popis: | Plasma total and nervous system derived exosomal (NDE) α-synuclein have been determined as potential biomarkers of Parkinson's disease (PD). To explore the utility of plasma α-synuclein in the prodromal phase of PD, plasma total and NDE α-synuclein were evaluated in baseline and 2-year follow-up samples from 256 individuals recruited as part of the Parkinson's Associated Risk Syndrome (PARS) study. The results demonstrated that baseline and longitudinal increases in total α-synuclein predicted progression of cognitive decline in hyposmic individuals with dopamine transporter (DAT) binding reduction. On the other hand, a longitudinal decrease in NDE α-synuclein predicted worsening cognitive scores in hyposmic individuals with DAT binding reduction. Finally, in individuals with faster DAT progression, decreasing NDE/total α-synuclein ratio was associated with a larger reduction in DAT from baseline to follow-up. These results suggest that, though underlying mechanisms remain to be defined, alterations in plasma total and NDE α-synuclein concentrations are likely associated with PD progression, especially in the aspect of cognitive impairment, at early stages of the disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect